<DOC>
	<DOCNO>NCT01846273</DOCNO>
	<brief_summary>This study compare effect ranibizumab administer monotherapy versus ranibizumab administer combination verteporfin PDT visual acuity patient symptomatic macular PCV . The result study provide long-term safety efficacy data use generate guidance management patient PCV .</brief_summary>
	<brief_title>Visual Outcome Patients With Symptomatic Macular PCV Treated With Either Ranibizumab Monotherapy Combined With Verteporfin Photodynamic Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Confirmed diagnosis symptomatic macular PCV study eye A qualify vision score study entry A qualify lesion size study eye study entry Active inflammation infection study eye Uncontrolled intraocular pressure stuy eye Ocular condition study eye may impact vision confound study outcomes Prior treatment study eye antiVEGF therapy , verteporfin PDT , laser surgical intervention , intraocular corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>